July 22, 2017 3:07 AM ET


Company Overview of Veracyte, Inc.

Company Overview

Veracyte, Inc. operates as a molecular diagnostics company in the United States. The company uses genomic technology to resolve diagnostic ambiguity. It offers Afirma Thyroid FNA Analysis solution for use in thyroid cancer diagnosis; cytopathology testing services; and the Afirma Malignancy Classifiers to manage thyroid nodule patients. The company’s products also include Percepta Bronchial Genomic Classifier solution for use in lung cancer screening and diagnosis; and Envisia Genomic Classifier solution for idiopathic pulmonary fibrosis. It sells its products through its product specialists, institutional channel managers, account managers, and clinical science specialists. The company was ...

6000 Shoreline Court

Suite 300

South San Francisco, CA 94080

United States

Founded in 2006

216 Employees





Key Executives for Veracyte, Inc.

Co-Founder, Chairman and Chief Executive Officer
Age: 59
Total Annual Compensation: $500.0K
President and Chief Operating Officer
Age: 48
Total Annual Compensation: $395.0K
Chief Financial Officer
Age: 47
Total Annual Compensation: $29.0K
Compensation as of Fiscal Year 2016.

Veracyte, Inc. Key Developments

Veracyte, Inc. Presents at The William Blair 2017 Growth Stock Conference, Jun-15-2017 08:00 AM

Veracyte, Inc. Presents at The William Blair 2017 Growth Stock Conference, Jun-15-2017 08:00 AM. Venue: The Four Seasons Hotel, 120 East Delaware Place, Chicago, IL 60611, United States. Speakers: Bonnie H. Anderson, Co-Founder, Chairman and Chief Executive Officer.

Veracyte, Inc. Presents at BIO International Conference 2017, Jun-22-2017 09:00 AM

Veracyte, Inc. Presents at BIO International Conference 2017, Jun-22-2017 09:00 AM. Venue: San Diego Convention Center, San Diego, CA 2865, United States. Speakers: John W. Hanna, Chief Commercial Officer.

Veracyte, Inc. Reports Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2017; Reiterates Earnings Guidance for the Year 2017

Veracyte, Inc. reported unaudited consolidated earnings results for the first quarter ended March 31, 2017. For the quarter, the company reported revenue of $16,432,000 against $13,550,000 a year ago. Loss from operations was $7,517,000 against $9,751,000 a year ago. Net loss and comprehensive loss was $8,217,000 or $0.24 per basic and diluted share against $10,075,000 or $0.36 per basic and diluted share a year ago. The company reiterated its 2017 annual revenue guidance of $76 million to $84 million and annual cash burn of $25 million to $27 million.

Similar Private Companies By Industry

Company Name Region
20n Labs, Inc. United States
23andMe, Inc. United States
2C Tech Corporation, Inc. United States
3-V Biosciences, Inc. United States
3Bar Biologics Inc. United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
The Advertising Council, Inc. United States
Rush University United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Veracyte, Inc., please visit www.veracyte.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.